2013;108:278–84. 22. Clark GM, Osborne CK, Levitt D, Wu F, Kim NW. Telomerase activity and survival of patients with node-positive breast cancer. J Natl Cancer Inst. 1997;89:1874–81. 23. Juratli TA, Thiede C, Koerner MVA, Tummala SS, Daubner D, Shankar GM, Williams EA, Martinez-Lage M, Soucek S, Robel K, et al. Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas. Oncotarget. 2017;8:109228. 24. Hugdahl E, Kalvenes MB, Mannelqvist M, Ladstein RG, Akslen LA. Prognostic impact and concordance of TERT promoter mutation and protein expres- sion in matched primary and metastatic cutaneous melanoma. Br J Cancer. 2018;118:98–105. 25. Laheurte C, Dosset M, Vernerey D, Boullerot L, Gaugler B, Gravelin E, Kaulek V, Jacquin M, Cuche L, Eberst G, et al. Distinct prognostic value of circulating anti-telomerase CD4(+ ) Th1 immunity and exhausted PD-1(+ )/TIM-3(+ ) T cells in lung cancer. Br J Cancer. 2019;121:405–16. 26.